CDC's Advisory Committee Backs Pneumococcal Vaccine From Pfizer, Merck

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer Inc's PFE Prevnar 20 pneumococcal vaccine for routine use.
The CDC's Advisory Committee has also voted to recommend vaccination either with a sequential regimen of Merck & Co Inc's PFE Vaxneuvance followed by Pneumovax 23 or with a single dose 20-valent pneumococcal conjugate vaccine.
These updates would apply to adults 65 years or older and adults with certain underlying medical conditions who have not previously received a pneumococcal conjugate vaccine or whose previous pneumococcal vaccination history is unknown.
Related Link: Merck's Pneumococcal Vaccine Lands FDA Nod, Just a Few Weeks After Its Rival.
Price Action: PFE shares are up 0.70% at $43.10, MRK shares are up 0.12% at $81.17 during the premarket session on the last check Thursday.